Literature DB >> 30102846

Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes.

Caterina Camodeca1, Elisa Nuti2, Francesca Tosetti3, Alessandro Poggi3, Cristina D'Arrigo4, Maria Raffaella Zocchi1, Armando Rossello2.   

Abstract

A disintegrin and metalloproteinase (ADAMs) are membrane-bound metalloproteases responsible for the ectodomain shedding of various transmembrane proteins and play important roles in multiple relevant biological processes. Their altered expression is involved in several pathological conditions, and in particular ADAM10 or ADAM17 overexpression is found in various forms of cancer. To better understand how they are regulated in the cellular context, it is useful to visualize the specific ADAMs pathway by means of molecular imaging techniques. For this purpose, we synthesized bioactive fluorescent probes suitable for cell imaging and that are able to specifically target ADAM10 or ADAM17. Two previously developed ADAM17- and ADAM10-selective inhibitors were chosen for conjugation, respectively, to a Cy5.5 dye and to Cy5.5 and FITC dyes. Herein we also report the synthesis of a gold-labeled compound as an additional bioimaging probe for ADAM10. The newly synthesized ligands were found to be active in vitro on human recombinant ADAM10 and/or ADAM17, showing IC50 values in the nanomolar range and a good selectivity over matrix metalloproteinases (MMPs). Finally, these newly developed probes were successfully used for ADAMs staining on different lymphoma cell lines and lymph node mesenchymal stromal cells.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  ADAM inhibitors; Hodgkin's lymphoma; fluorescent probes; nanoparticles

Mesh:

Substances:

Year:  2018        PMID: 30102846     DOI: 10.1002/cmdc.201800482

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  5 in total

Review 1.  Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease.

Authors:  Namdoo Kim; Hyuck Jin Lee
Journal:  Biomed Res Int       Date:  2020-11-09       Impact factor: 3.411

2.  The metalloproteinase ADAM10 requires its activity to sustain surface expression.

Authors:  Anke Seifert; Stefan Düsterhöft; Justyna Wozniak; Chek Z Koo; Michael G Tomlinson; Elisa Nuti; Armando Rossello; Doretta Cuffaro; Daniela Yildiz; Andreas Ludwig
Journal:  Cell Mol Life Sci       Date:  2020-05-05       Impact factor: 9.261

3.  Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors.

Authors:  Doretta Cuffaro; Caterina Camodeca; Tiziano Tuccinardi; Lidia Ciccone; Jörg W Bartsch; Tanja Kellermann; Lena Cook; Elisa Nuti; Armando Rossello
Journal:  ACS Med Chem Lett       Date:  2021-10-08       Impact factor: 4.345

4.  Development of a fluorogenic ADAMTS-7 substrate.

Authors:  Salvatore Santamaria; Frederic Buemi; Elisa Nuti; Doretta Cuffaro; Elena De Vita; Tiziano Tuccinardi; Armando Rossello; Steven Howell; Shahid Mehmood; Ambrosius P Snijders; Rens de Groot
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

5.  Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.

Authors:  Roberta Pece; Sara Tavella; Delfina Costa; Serena Varesano; Caterina Camodeca; Doretta Cuffaro; Elisa Nuti; Armando Rossello; Massimo Alfano; Cristina D'Arrigo; Denise Galante; Jean-Louis Ravetti; Marco Gobbi; Francesca Tosetti; Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.